Virology Research Today is a free monthly online journal that collates and summarizes the latest research about Virology, including details on viruses, pathology, classification, definitions.

Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab.

Cheung WW, Tse E, Leung AY, Yuen KY, Kwong YL

Department of Medicine, Queen Mary Hospital, Hong Kong.

Ten patients with refractory lymphomas or autoimmune cytopenias were treated with alemtuzumab, and monitored prospectively for cytomegalovirus (CMV) reactivation by antigenemia and polymerase chain reaction. All patients showed virologic CMV reactivation. Two patients developed pneumonitis and hepatitis respectively, necessitating alemtuzumab withdrawal. Eight patients were asymptomatic, and with pre-emptive anti-CMV treatment, alemtuzumab therapy was uninterrupted. All patients ultimately achieved virologic remission. The frequent CMV reactivation was due to a high background seropositivity rate for CMV, severely immunocompromized patients, a sensitive detection method, and the diligence of surveillance. Frequent monitoring for and early treatment of CMV reactivation is necessary during alemtuzumab therapy.

Published 11 January 2007 in Am J Hematol, 82(2): 108-11.
Full-text of this article is available online (may require subscription).

© 2005-2008 Virology Research Today. All Rights Reserved.